Attached files

file filename
EX-99.1 - HARROW HEALTH, INC.ex99-1.htm
EX-10.1 - HARROW HEALTH, INC.ex10-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 28, 2017

 

IMPRIMIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35814   45-0567010
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

12264 El Camino Real, Suite 350    
San Diego, CA   92130
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4040

 

N/A

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On April 28, 2017, Imprimis Pharmaceuticals, Inc. (the “Company”) entered into a Strategic Sales & Marketing Agreement (the “Agreement”) with SightLife Surgical, Inc. (“SightLife”). Pursuant to the terms of the Agreement, SightLife will provide exclusive United States sales and marketing representation services to the Company in connection with the Company’s autologous serum tears compound formulation (the “Products”).

 

Under the terms of the Agreement, the Company is required to make commission payments to SightLife equal to ten percent (10%) of each calendar year’s annual net sales for Products. In addition, the Company is required to make certain periodic milestone payments to SightLife in shares of the Company’s restricted common stock including: (i) 5,000 shares if net sales for Products reach $2,000,000 prior to December 31, 2017; (ii) 7,500 shares if net sales for Products reach $2,500,000; (iii) 7,500 shares if net sales for Products reach $5,000,000; (iv) 7,500 shares if net sales for Products reach $7,500,000; and (v) 7,500 shares if net sales for Products reach $10,000,000.

 

The foregoing is only a brief description of the Agreement does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the full text of the document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits.

 

Exhibit No.   Description
10.1   Strategic Sales & Marketing Agreement dated April 28, 2017 between Imprimis Pharmaceuticals, Inc. and SightLife Surgical, Inc.
     
99.1   Press Release issued by Imprimis Pharmaceuticals, Inc. on May 2, 2017.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMPRIMIS PHARMACEUTICALS, INC.
     
Dated: May 2, 2017 By: /s/ Andrew R. Boll
  Name: Andrew R. Boll
  Title: Chief Financial Officer